Clinical Trials Directory

Trials / Completed

CompletedNCT03973723

Plasma EBV DNA Monitoring in Post-treatment NPC Patients

Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment

Status
Completed
Phase
Study type
Observational
Enrollment
441 (actual)
Sponsor
Taichung Veterans General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Continuous regular monitoring of plasma EBV DNA in nasopharyngeal carcinoma (NPC) after treatment have rarely been investigated. The investigators try to analyze the long-term observational results (role in early relapse detection and impact on survival) in NPC patients after curative treatment.

Detailed description

The investigators enrolled 441 NPC patients who had finished finished curative radiotherapy with/without chemotherapy and no recurrence/metastasis before entry this study from five hospitals in Taiwan. Blood samples were collected on the day of enrollment and monitored once every 2-3 months for plasma EBV DNA measurement. After long-term observation, we analyze the impact of continuous plasma EBV DNA monitoring on the early dection of tumor relapse and do risk grouping for survival analyses according to the blood test results.

Conditions

Timeline

Start date
2011-08-01
Primary completion
2013-12-31
Completion
2019-04-30
First posted
2019-06-04
Last updated
2019-06-07

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03973723. Inclusion in this directory is not an endorsement.